09.20.16
Organic Technologies, producer of AlaskOmega omega-3 fish oil and omega-7 concentrates, presented an investigative review of omega-7 (C16:1 palmitoleic acid) at the 12th Congress of the International Society for the Study of Fatty Acids and Lipids (ISSFAL) in South Africa. ISSFAL, established in 1991 with the objective of increasing the understanding of dietary fatty acids and lipids in health and disease through research and education, boasts over 500 members from more than forty countries and includes scientists, health professionals, and educators.
Gretchen Vannice, MS, a registered dietitian nutritionist with an extensive background in dietary lipids, co-chaired and opened the ISSFAL omega-7 session, reviewing a wide range of research conducted over the past 15 years on the potential health benefits of palmitoleic acid, including heart health, insulin sensitivity, and reducing inflammation. “Little is known about the role of cis palmitoleic acid (POA) in human health. It is a unique monounsaturated fat,” remarked Gretchen Vannice, head of global nutrition education at Organic Technologies. “Animal studies consistently report promising effects on markers of diabetes and inflammation and one short-term supplement trial suggests beneficial effects on blood lipids, but how these findings translate into human health benefit is unclear,” continued Ms. Vannice. “Certainly, more human and mechanistic research is needed and it’s great to see Organic Technologies take the lead on this.”
Organic Technologies is actively conducting clinical studies with leading researchers worldwide to document effects of its AlaskOmega Omega-7 Palmitoleic 500, a highly concentrated form (min. 50% omega-7), allowing food, supplement, and cosmetic formulators to achieve higher, purified omega-7 levels at a more competitive price.
For more information: http://alaskomega.com
Gretchen Vannice, MS, a registered dietitian nutritionist with an extensive background in dietary lipids, co-chaired and opened the ISSFAL omega-7 session, reviewing a wide range of research conducted over the past 15 years on the potential health benefits of palmitoleic acid, including heart health, insulin sensitivity, and reducing inflammation. “Little is known about the role of cis palmitoleic acid (POA) in human health. It is a unique monounsaturated fat,” remarked Gretchen Vannice, head of global nutrition education at Organic Technologies. “Animal studies consistently report promising effects on markers of diabetes and inflammation and one short-term supplement trial suggests beneficial effects on blood lipids, but how these findings translate into human health benefit is unclear,” continued Ms. Vannice. “Certainly, more human and mechanistic research is needed and it’s great to see Organic Technologies take the lead on this.”
Organic Technologies is actively conducting clinical studies with leading researchers worldwide to document effects of its AlaskOmega Omega-7 Palmitoleic 500, a highly concentrated form (min. 50% omega-7), allowing food, supplement, and cosmetic formulators to achieve higher, purified omega-7 levels at a more competitive price.
For more information: http://alaskomega.com
